- Home
- PLXS vs AKRO Comparison
PLXS vs AKRO Comparison
Compare PLXS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- AKRO
- Stock Information
- Founded
- PLXS 1979
- AKRO 2017
- Country
- PLXS United States
- AKRO United States
- Employees
- PLXS N/A
- AKRO N/A
- Industry
- PLXS Electrical Products
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- AKRO Health Care
- Exchange
- PLXS Nasdaq
- AKRO Nasdaq
- Market Cap
- PLXS 3.6B
- AKRO 3.9B
- IPO Year
- PLXS 1986
- AKRO 2019
- Fundamental
- Price
- PLXS $131.26
- AKRO $49.65
- Analyst Decision
- PLXS Buy
- AKRO Strong Buy
- Analyst Count
- PLXS 4
- AKRO 8
- Target Price
- PLXS $157.33
- AKRO $82.50
- AVG Volume (30 Days)
- PLXS 126.5K
- AKRO 1.9M
- Earning Date
- PLXS 07-23-2025
- AKRO 05-12-2025
- Dividend Yield
- PLXS N/A
- AKRO N/A
- EPS Growth
- PLXS 41.85
- AKRO N/A
- EPS
- PLXS 5.14
- AKRO N/A
- Revenue
- PLXS $3,967,612,000.00
- AKRO N/A
- Revenue This Year
- PLXS $4.62
- AKRO N/A
- Revenue Next Year
- PLXS $9.00
- AKRO N/A
- P/E Ratio
- PLXS $25.53
- AKRO N/A
- Revenue Growth
- PLXS N/A
- AKRO N/A
- 52 Week Low
- PLXS $100.96
- AKRO $17.86
- 52 Week High
- PLXS $172.89
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PLXS 54.58
- AKRO 63.34
- Support Level
- PLXS $127.94
- AKRO $44.94
- Resistance Level
- PLXS $133.98
- AKRO $49.29
- Average True Range (ATR)
- PLXS 2.92
- AKRO 3.33
- MACD
- PLXS -0.12
- AKRO 0.67
- Stochastic Oscillator
- PLXS 54.55
- AKRO 86.02
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.